ArborGen and Vallourec Sign Eucalyptus Commercialisation Agreement
Today, ArborGen, a world leader in the development and commercialisation of technologies that improve the productivity of trees, announced that it has entered into an agreement with Vallourec S.A. that gives ArborGen exclusive rights to develop and commercialise Vallourecs genetically improved eucalyptus clones in Brazil.
- Today, ArborGen, a world leader in the development and commercialisation of technologies that improve the productivity of trees, announced that it has entered into an agreement with Vallourec S.A. that gives ArborGen exclusive rights to develop and commercialise Vallourecs genetically improved eucalyptus clones in Brazil.
- ArborGen is one of the largest commercial suppliers of eucalyptus and pine tree seedlings in Brazil.
- ArborGen already has exclusive rights to commercialise International Papers and Gerdaus eucalyptus clones in Brazil, and continues to also develop its own proprietary eucalyptus clones which it is beginning to commercialise.
- Gabriela Monnerat, the General Manager of ArborGen Brazil, said, The agreement with Vallourec allows ArborGen to provide new clones that offer growers high yields and high wood density.